[A new approach to the prevention and treatment of lesions caused by bacterial toxins: prospects for using inhibitors of ADP ribosylation].
The damaging action of a number of bacterial toxins is determined by their capacity for blocking the specific functions of regulatory proteins of eukaryotic cells by ADP-ribosylation. Experiments, made with the use of type B botulinic toxin and 3,N-butyrylaminobenzamide as an example, have demonstrated that specific ADP-ribosylation inhibitors are capable of making up a new group of highly active antagonists of microbial toxins.
Krasil'nikov
I I
II
Research Institute of Military Medicine, St.-Petersburg, Russia.
Stepanov
A V
AV
Misnikova
M A
MA
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use* / Q000633:toxicity; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors*; D001549:Benzamides / Q000627:therapeutic use* / Q000633:toxicity; D001905:Botulinum Toxins / Q000037:antagonists & inhibitors / Q000633:toxicity; D001906:Botulism / Q000188:drug therapy / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D013997:Time Factors
D000890:Anti-Infective Agents; D001427:Bacterial Toxins; D001549:Benzamides; C088105:3-(N-butyrylamino)benzamide; D001905:Botulinum Toxins